Drug concentration (μM)

Slides:

Advertisements

Similar presentations

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.

Advertisements

Supplementary Figure S1.

Volume 49, Issue 1, Pages (January 2006)

Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model Jie Li, Ni Hou, Ahmad Faried, Soichi Tsutsumi,

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration- resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo

B A P-AXL P-AXL AXL AXL P-MET P-MET MET MET P-Akt-473 P-Akt-473 AKT

A Novel Cinnamide YLT26 Induces Breast Cancer Cells Apoptosis via ROS-Mitochondrial Apoptotic Pathway in Vitro and Inhibits.

Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in.

The Combined Effects of Hematoporphyrin Monomethyl Ether-SDT and Doxorubicin on the Proliferation of QBC939 Cell Lines Lei Liang, Sheng Xie, Lin Jiang,

Saikosaponin-D Enhances Radiosensitivity of Hepatoma Cells under Hypoxic Conditions by Inhibiting Hypoxia-Inducible Factor-1α Cell Physiol Biochem 2014;33:37-51.

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib Yiyu Zou, PhD, Yi-He.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Combination therapy for adult T-cell leukemia–xenografted mice: flavopiridol and anti-CD25 monoclonal antibody by Meili Zhang, Zhuo Zhang, Carolyn K. Goldman,

Volume 49, Issue 1, Pages (January 2006)

Molecular Therapy - Oncolytics

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis Dao M Nguyen, MD, Dominique.

3,3′,4,4′,5,5′-Hexahydroxystilbene Impairs Melanoma Progression in a Metastatic Mouse Model Verena Paulitschke, Nikolaus Schicher, Thomas Szekeres, Walter.

A PC-9 PC-9/AR B PC-9/GR PC-9/GR/AR AZD9291 AZD9291 AZD9291 AZD9291

Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo by Min.

Volume 19, Issue 1, Pages (January 2017)

Effects of Betulinic Acid Alone and in Combination with Irradiation in Human Melanoma Cells Edgar Selzer, Emilio Pimentel, Volker Wacheck, Werner Schlegel,

NF1 silencing confers resistance of PC9 lung adenocarcinoma cells to erlotinib (erl). NF1 silencing confers resistance of PC9 lung adenocarcinoma cells.

A B Supplementary Figure 3

by Jun Yuan, David B. Lovejoy, and Des R. Richardson

Kejie Zhang, Michael Wang, Archito T

The Survival Effect of Prolactin on PC3 Prostate Cancer Cells

MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib Yiyu Zou, PhD, Yi-He.

BV6 increases tumor burden in bone.

Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer Tadaaki Yamada, MD, PhD, Shinji Takeuchi,

Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation Silvia La Monica,

Protodynamic Intracellular Acidification by cis-Urocanic Acid Promotes Apoptosis of Melanoma Cells In Vitro and In Vivo Jarmo K. Laihia, Janne P. Kallio,

Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis

PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.

Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non– Small Cell Lung Cancer Xenograft Models Josephine Hai, PhD, Shingo Sakashita,

AT-101, a Pan-Bcl-2 Inhibitor, Leads to Radiosensitization of Non-small Cell Lung Cancer Luigi Moretti, MD, Bo Li, MD, Kwang Woon Kim, PhD, Heidi Chen,

Inhibition of β-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation Yosuke.

Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer Jasmine.

Volume 27, Issue 1, Pages (January 2015)

Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer Edward.

miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK

Inhibition of β-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation Yosuke.

Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines Wei Zhang, PhD, Michael.

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation Junya Nakade,

Imipramine and promethazine induce the apoptotic cell death of SCLC cells through activation of caspase-3. Imipramine and promethazine induce the apoptotic.

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

Fig. 3. TKI sensitivity assessed by the MANO method.

Thomas S. Griffith, Elizabeth L. Broghammer Molecular Therapy

Molecular Therapy - Nucleic Acids

Role of HER2 in mediating acquired resistance to EGFR inhibition.

Supplemental Figure 6 Supplemental Figure 6. Treatment with erlotinib plus TAS-115 inhibits the growth of PC-9/HGF tumors in vivo. (A, B) Nude mice bearing.

MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity

Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib Kenichi.

Confirmation of synergy and cytotoxicity of genotype-selective drug pairs. Confirmation of synergy and cytotoxicity of genotype-selective drug pairs. A,

Volume 18, Issue 3, Pages (March 2010)

Volume 22, Issue 2, Pages (February 2014)

SEMA3C regulates prostate cancer cell growth

A, chemical structures of PRIMA-1 and PRIMA-1Met.

Volume 20, Issue 4, Pages (April 2012)

N-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. n-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. HEC-1-A.

A B HPAF-II CFPAC-1 cells Drug concentration, µM 50

Effect of siltuximab on paclitaxel sensitivity in ovarian cancer drug resistant cells. Effect of siltuximab on paclitaxel sensitivity in ovarian cancer.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer cell growth. Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer.

Heterogeneous resistance mechanisms develop in response to W+T combination treatment in the EGFRL858R/T790M genetically engineered mice. Heterogeneous.

THZ1 in combination with targeted therapy enhances cell death and hinders the establishment of drug-resistant colonies in diverse oncogene-addicted cellular.

Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated breast cancer cells. Elevated STAT3 phosphorylation and RANTES levels in tamoxifen-treated.

MET activation confers resistance to cetuximab (Cmab) or panitumumab (Pmab) in colon cancer cell lines in vitro and in vivo. MET activation confers resistance.

Presentation transcript:

Drug concentration (μM) % cell viability Drug concentration (μM) HCC827ER HGF(+) HGF(-) Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing concentrations of EGFR-TKI, erlotinib, or 17-DMAG, with or without HGF (20 ng/ml), and cell growth was determined after 72 hours by MTT assay. Data shown are the representative of 3 independent experiments. Error bars indicate SD of triplicate cultures.

Drug concentration (μM) % cell viability PC-9 HGF(+) Ma-1/HGF H1975 HGF(+) PC-9 HGF(-) H1975 HGF(-) Supplementary Figure 2. The effect of combined therapy with 17-DMAG and EGFR-TKI on the growth of lung cancer cells with mutated EGFR Tumor cells were continuously treated with increasing concentrations of EGFR-TKI, erlotinib (PC-9 and Ma-1/HGF), CL-387,785 (H1975), or 17-DMAG, with or without HGF (20 ng/ml), and cell growth was determined after 72 hours by MTT assay. Data shown are the representative of 3 independent experiments. Error bars indicate SD of triplicate cultures.

Supplementary Figure 3. HGF (ng/ 2×105cells) < 0.1 < 0.1

Ma-1 Ma-1/Vec PI Ma-1/HGF AnnexinV 2.90 31.52 35.49 3.05 5.44 24.89 1.64 14.01 12.11 0.69 2.85 15.64 2.64 4.04 17.81 Control Erlotinib 17-DMAG HGF HGF+Erlotinib HGF+17-DMAG Ma-1 PI Ma-1/Vec Ma-1/HGF AnnexinV Supplementary Figure 4. 17-DMAG induces apoptosis even in the presence of HGF. Ma-1, Ma-1/Vec, and Ma-1/HGF cells were incubated with HGF (20 ng/mL) and erlotinib (0.3 μmol/L) or 17-DMAG (0.3 μmol/L) for 48 hour and washed twice with PBS. The apoptotic cells were determined by Annexin V assays according to the manufactor’s protocol. Values shown are percentage of apoptotic cells. FL1-H and FL2-H, heights of fluorescence intensity.

A C 1 5 2 6 3 7 4 8 B 1: Ma-1 Control 2: Ma-1 Erlotinib 3: Ma-1 17-DMAG 4: Ma-1 Combination 5: Ma-1/HGF Control 6: Ma-1/HGF Erlotinib 7: Ma-1/HGF 17-DMAG 8: Ma-1/HGF Combination Supplementary Figure 5. The effect of combination treatment with 17-DMAG plus erlotinib to HGF-induced erlotinib resistance in vivo. Ma-1 /Vec (A) or Ma-1/HGF (B) (5 × 106) cells were inoculated subcutaneously into SCID mice on day 0. Mice received oral erlotinib (20 mg/kg/d) and/or intraperitoneal 17-DMAG (10 mg/kg/d), starting on day 7. Tumor size was measured twice a week and tumor volumes were calculated as described in Materials and Methods. Error bars indicate standard errors of 6tumors. C, macroscopic appearances of representative tumors harvested on day 21.

Supplementary Figure 6. Control Erlotinib 17-DMAG Ma-1/Vec Ma-1/HGF

Supplementary Figure 7. Control Erlotinib 17-DMAG Ma-1/Vec Ma-1/HGF